Nascent Pharma Holdings's total inventories for the quarter that ended in Sep. 2024 was $0.16 Mil. Nascent Pharma Holdings's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $0.36 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Nascent Pharma Holdings's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-0.27.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Nascent Pharma Holdings's Days Inventory for the
three
months ended in Sep. 2024 was 78.86.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Nascent Pharma Holdings's Inventory Turnover for the quarter that ended in Sep. 2024 was 1.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nascent Pharma Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 23.97.
Nascent Pharma Holdings (OTCPK:NASC) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Nascent Pharma Holdings's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nascent Pharma Holdings's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Nascent Pharma Holdings Total Inventories Related Terms
Nascent Pharma Holdings Total Inventories Historical Data
* Premium members only.
The historical data trend for Nascent Pharma Holdings's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nascent Pharma Holdings Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Nascent Pharma Holdings (NASC) has a Total Inventories of $0.16 Mil as of Sep. 2024. The total amount of inventory as recorded on a company's balance sheet. View historical data for Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Total Inventories too high?
Nascent Pharma Holdings' current Total Inventories is $0.16 Mil. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Total Inventories compare to ALID and CPMD?
Nascent Pharma Holdings' Total Inventories of $0.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Total Inventories is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Total Inventories of $0.16 Mil. The current Total Inventories is $0.16 Mil. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Total Inventories is $0.16 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score
Get the complete analysis for NASC
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NASC has been successfully added to your 
